Related Experiment Video
Updated: Oct 26, 2025
09:06
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
8.5K
Research Progress on Catalpol as Treatment for Atherosclerosis
Lei He1, Rusheng Zhao1, Youheng Wang1
1Department of Cardiology, The First Affiliated Hospital of Xinxiang Medical University, Heart Center of Xinxiang Medical University, Xinxiang, China.
Frontiers in Pharmacology
|July 30, 2021
Summary
Catalpol, derived from traditional Chinese medicine, shows promise in combating atherosclerosis (AS). This review highlights its potential to reduce atherosclerotic plaque formation through anti-inflammatory and antioxidant mechanisms in animal models.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Traditional Chinese Medicine
Background:
- Atherosclerosis (AS) is a primary pathological change underlying major cardiovascular diseases like myocardial infarction and stroke, contributing significantly to global mortality.
- Traditional Chinese medicine and its active compounds offer potential therapeutic strategies for AS.
- Catalpol, an iridoid terpene from Rehmannia glutinosa, possesses anti-inflammatory and antioxidant properties, with documented effects on various health conditions.
Purpose of the Study:
- To review the effects of catalpol on atherosclerotic plaque formation in animal models.
- To summarize the potential mechanisms by which catalpol ameliorates AS.
Main Methods:
- Literature review focusing on studies investigating catalpol's impact on atherosclerosis.
- Analysis of research examining catalpol's mechanisms of action, including oxidative stress, inflammation, cellular aging, apoptosis, and SIRT1 pathway activation.
Main Results:
- Catalpol demonstrated efficacy in reducing atherosclerotic plaque formation across various animal models.
- Key mechanisms involved in catalpol's anti-atherosclerotic effects include mitigation of oxidative stress and inflammation, regulation of cellular aging and apoptosis, and modulation of the SIRT1 pathway.
Conclusions:
- Catalpol shows significant therapeutic potential for treating atherosclerosis.
- Further research into catalpol's mechanisms could lead to novel pharmacological interventions for AS.
Related Concept Videos
01:26Atherosclerosis III: Management
80
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
80
01:27Peripheral Artery Disease III: Interprofessional Care
82
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
82
01:30Atherosclerosis I: Introduction
260
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
260
01:27Coronary Artery Disease V: Interprofessional Care
74
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
74
01:30Coronary Artery Disease I: Introduction
542
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
542
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
292
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
292